Donate
Youtube Instagram Facebook

Gen Y Event

November 21, 2022
Events
1 min read

Our recent Gen Y event was amazing! Thank you to everyone who attended, and a special thanks to our Gen Y Event Co-Chairs, Morgan Weinblatt and Julia Pratt, who brought together more than 75 of their peers to learn more about BRCA mutations, hereditary cancers, the importance of knowing your risks, and where, how and when to get tested.

Guests had the opportunity to hear from Yodeah Founder, Dr. Liz Etkin-Kramer, as well as Gerry Riemer, and Morgan, who shared their personal BRCA stories and the actions they have taken for themselves and their future families.

Thank you to our sponsors and partners: Florida Breast Cancer Foundation, E11EVEN Vodka, Greater Miami Jewish Federation & its Young Leadership Division, The Tribe, and Base Miami.

Do you know your risks? #GetTested for yourself, your family, and generations to come!

You may also like
News Featured

Sharsheret and Yodeah Educate Women About Breast Cancer

In honor of Women’s History Month, our Women’s Philanthropy division wants you to know about Federation’s efforts to improve the lives of Jewish Women everywhere. Our Women’s Impact Initiative Grants are supporting two organizations that help Jewish women understand their […]

September 27, 20241 min read
Events

Life Is Amazing

On September 25th, 2021 BRCASTRONG invites you to join us at our event “Life is Amazing”https://www.eventbrite.com/e/life-is-amazing-tickets-164326861065

September 25, 20211 min read

THE MOST RELEVANT GENES FOR COMMON HEREDITARY CANCERS

* CDK4: analysis is limited to chr12:g.58145429-58145431 (codon 24). EPCAM: analysis is limited to deletions that minimally encompass the 3′ end of the gene including exons 8 and/or 9. GREM1: analysis is limited to duplications that overlap the upstream regulatory region. MITF: analysis is limited to chr3:g.70014091 (including c.952G>A). MUTYH: single heterozygous pathogenic variants, likely pathogenic variants, and variants of uncertain significance are not reported. PMS2: variants of uncertain significance are not reported for exons 12-15. Analysis excludes three variants commonly observed in the pseudogene PMS2CL: c.2182_2184delinsG, c.2243_2246delAGAA and deletion of exons 13-14 (chr7:g.6015768_6018727del). POLD1: analysis is limited to chr19:g.50909713 (including c.1433G>A). POLE: analysis is limited to chr12:g.133250250 (including c.1270C>G).